That’s probably prelude. The secondary is hard to swallow.
I would be buying some shares back over time, probably not all though.
My thinking is the market will start to shift the focus to ENTA immunology side of the business regardless of what happen with RSV. And that would mean much higher valuations
RSV, as you said, the data is solid, maybe too good for Jay to not for bargaining for some or maybe even a lot more, which might take time. I wanted it to close the RSV chapter soon but guess this outcome is not the worst neither
But again, my best hope is someone just buy us out, which I think it’s more likely than ever.
Market Data 
Markets 
AI
